Randomized trial · people

Melanotan I plus UV-B: 48.64% vitiligo repigmentation at day 168

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, adding afamelanotide to UV-B light brought color back to vitiligo patches faster and more fully than light alone, mainly in darker skin types.

Kind
Randomized trial
Studied in
People
Published
2015
Journal
JAMA Dermatol

What they tested

Does adding an afamelanotide implant to narrowband UV-B light therapy work better and stay safe for widespread vitiligo, compared with the light therapy alone?

How the study was done

A randomized trial at 3 dermatology sites in adults with nonsegmental vitiligo covering 15% to 50% of the body and skin types III to VI. After 1 month of narrowband UV-B light, 28 people also got a 16 mg afamelanotide implant under the skin once a month for 4 months, while 27 stayed on UV-B light alone.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Melanotan I? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

By day 56, people getting both treatments had a statistically significant better response than those on light alone. More people in the combined group regained color on the face and upper extremities, and they did so sooner: 41.0 vs 61.0 days for the face and 46.0 vs 69.0 days for the upper extremities. At day 168, repigmentation (color returning to pale patches) was 48.64% with the combination vs 33.26% with light alone. The gain showed up in skin types IV to VI but not in skin type III; both groups had skin redness, and the combined group also had nausea and minor infections.

What it doesn’t show

This was a small trial, with 28 and 27 people in the two groups, and afamelanotide was given for only 4 months. It tested afamelanotide only together with UV-B light, not on its own, and the benefit was not significant in lighter skin type III.

The paper

Lim et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015.

The compound

More studies on Melanotan I

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Melanotan I? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo